Almotriptan joins migraine market.
D000075202:Contraindications; D017277:Drug Approval; D006801:Humans; D007211:Indoles / Q000008:administration & dosage*; D008881:Migraine Disorders / Q000188:drug therapy*; D016032:Randomized Controlled Trials as Topic; D012449:Safety; D017366:Serotonin Receptor Agonists / Q000008:administration & dosage*; D014481:United States; D014486:United States Food and Drug Administration
D007211:Indoles; D017366:Serotonin Receptor Agonists